Active surveillance of prostate cancer: A questionnaire survey of urologists, clinical oncologists and urology nurse specialists across three cancer networks in the United Kingdom

BMC Urology

Volumn 15, Issue 1, 2015, Pages

  Philippou, Yiannis ^a   Raja, Hary ^b   Gnanapragasam, Vincent J ^b  

^a BASILDON HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Active surveillance; Prostate cancer; Questionnaire survey

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ACTIVE SURVEILLANCE; ADULT; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER RISK; CLINICAL NURSE SPECIALIST; CONTROLLED STUDY; FOLLOW UP; HEALTH SURVEY; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLOGIST; PATIENT COUNSELING; PROSTATE CANCER; RISK ASSESSMENT; TUMOR VOLUME; UNITED KINGDOM; UROLOGIST; CANCER STAGING; CLINICAL PRACTICE; CLINICAL TRIAL; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; IMMUNOHISTOCHEMISTRY; MULTICENTER STUDY; NEEDLE BIOPSY; NEPHROLOGY NURSING; ONCOLOGY; PATHOLOGY; PATIENT SAFETY; PROCEDURES; PROSTATIC NEOPLASMS; QUESTIONNAIRE; STATISTICS AND NUMERICAL DATA; TUMOR INVASION; UROLOGY; WATCHFUL WAITING;

BIOPSY, NEEDLE; CROSS-SECTIONAL STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MEDICAL ONCOLOGY; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEPHROLOGY NURSING; PATIENT SAFETY; PRACTICE PATTERNS, PHYSICIANS'; PROSTATIC NEOPLASMS; SURVEYS AND QUESTIONNAIRES; UNITED KINGDOM; UROLOGY; WATCHFUL WAITING;

EID: 84931265202     PISSN: None     EISSN: 14712490     Source Type: Journal    
DOI: 10.1186/s12894-015-0049-y     Document Type: Article

References (18)

1. Thompson I, Trasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, et al. AUA Prostate Cancer Clinical Guideline Update Panel. Guideline for the management of clinically localised prostate cancer: 2007 update. J Urol. 2007;177:2106-31.
2. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EUA guidelines on prostate cancer. Part 1: screening, diagnosis and treatment of clinically localised disease. Eur Urol. 2011;59:61-71.
3. Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012;367:203-13.
4. Dall'Era MA, Albertsen PC, Bangma C, Caroll PR, Carter HB, Cooperberg MR, et al. Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol. 2012;62:976-83.
5. NICE guideline on prostate cancer: diagnosis and treatment. February 2014 (CG175). Available at http://www.nice.org.uk/guidance/cg175. Accessed October 2014
6. National Institute for Health and Clinical Excellence. Costing statement: prostate cancer: diagnosis and treatment. Implementing the NICE guidance on prostate treatment(CG175). Available at: https://www.nice.org.uk/guidance/cg175/resources/cg175-prostate-cancer-costing-statement2. Accessed August 2014
7. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320-8.
8. Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2011;364:1708-17.
9. Cancer Care Ontario. Active surveillance for the management of localized prostate cancer. Available at www.cancercare.on.ca. Accessed March 2015
10. Bul M, van den Bergh RC, Zhu X, Rannikko A, Vasarainen H, Bangma CH, et al. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer. BJU Int. 2012;110:1672-7.
11. Dall'Era MA, Konety BR, Cowan JE, Shinohara K, Stauf F, Cooperberg MR, et al. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer. 2008;112:2664-70.
12. Soloway MS, Soloway CT, Eldefrawy A, Soloway MS, Soloway CT, Eldefrawy A, et al. Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment. Eur Urol. 2010;58:831-5.
13. Ercole B, Marietti SR, Fine J, Albertsen PC. Outcomes following active surveillance of men with localized prostate cancer diagnosed in the prostate specific antigen era. J Urol. 2008;180:1336-9.
14. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol. 2010;28:126-31.
15. Ischia JJ, Pang CY, Tay YK, Suen CF, Aw HC, Frydenberg M. Active surveillance for prostate cancer: an Australian experience. BJU Int. 2012;109:40-3.
16. Thomsen FB, Roder MA, Hvarness H, Iversen P, Brasso K. Active surveillance can reduce overtreatment in patients with low-risk prostate cancer. Dan Med J. 2013;60:A4575.
17. Selvadurai ED, Singhera M, Thomas K, Mohammed K, Woode-Amissah R, Horwich A, et al. Medium-term outcomes of active surveillance for localised prostate cancer. Eur Urol. 2013;64:981-7.
18. Tosoian JJ, Trock BJ, Landis P, Feng Z, Epstein JI, Partin AW, et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol. 2011;29:2185-90.